Literature DB >> 22306323

A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index.

David Ulmert1, Reza Kaboteh, Josef J Fox, Caroline Savage, Michael J Evans, Hans Lilja, Per-Anders Abrahamsson, Thomas Björk, Axel Gerdtsson, Anders Bjartell, Peter Gjertsson, Peter Höglund, Milan Lomsky, Mattias Ohlsson, Jens Richter, May Sadik, Michael J Morris, Howard I Scher, Karl Sjöstrand, Alice Yu, Madis Suurküla, Lars Edenbrandt, Steven M Larson.   

Abstract

BACKGROUND: There is little consensus on a standard approach to analysing bone scan images. The Bone Scan Index (BSI) is predictive of survival in patients with progressive prostate cancer (PCa), but the popularity of this metric is hampered by the tedium of the manual calculation.
OBJECTIVE: Develop a fully automated method of quantifying the BSI and determining the clinical value of automated BSI measurements beyond conventional clinical and pathologic features. DESIGN, SETTING, AND PARTICIPANTS: We conditioned a computer-assisted diagnosis system identifying metastatic lesions on a bone scan to automatically compute BSI measurements. A training group of 795 bone scans was used in the conditioning process. Independent validation of the method used bone scans obtained ≤3 mo from diagnosis of 384 PCa cases in two large population-based cohorts. An experienced analyser (blinded to case identity, prior BSI, and outcome) scored the BSI measurements twice. We measured prediction of outcome using pretreatment Gleason score, clinical stage, and prostate-specific antigen with models that also incorporated either manual or automated BSI measurements. MEASUREMENTS: The agreement between methods was evaluated using Pearson's correlation coefficient. Discrimination between prognostic models was assessed using the concordance index (C-index). RESULTS AND LIMITATIONS: Manual and automated BSI measurements were strongly correlated (ρ=0.80), correlated more closely (ρ=0.93) when excluding cases with BSI scores≥10 (1.8%), and were independently associated with PCa death (p<0.0001 for each) when added to the prediction model. Predictive accuracy of the base model (C-index: 0.768; 95% confidence interval [CI], 0.702-0.837) increased to 0.794 (95% CI, 0.727-0.860) by adding manual BSI scoring, and increased to 0.825 (95% CI, 0.754-0.881) by adding automated BSI scoring to the base model.
CONCLUSIONS: Automated BSI scoring, with its 100% reproducibility, reduces turnaround time, eliminates operator-dependent subjectivity, and provides important clinical information comparable to that of manual BSI scoring.
Copyright © 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22306323      PMCID: PMC3402084          DOI: 10.1016/j.eururo.2012.01.037

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  15 in total

1.  Cardiovascular risk groups and mortality in an urban swedish male population: the Malmö Preventive Project.

Authors:  G Berglund; K F Eriksson; B Israelsson; T Kjellström; F Lindgärde; I Mattiasson; J A Nilsson; L Stavenow
Journal:  J Intern Med       Date:  1996-06       Impact factor: 8.989

2.  Computer-assisted interpretation of planar whole-body bone scans.

Authors:  May Sadik; Iman Hamadeh; Pierre Nordblom; Madis Suurkula; Peter Höglund; Mattias Ohlsson; Lars Edenbrandt
Journal:  J Nucl Med       Date:  2008-11-07       Impact factor: 10.057

Review 3.  Prostate kallikrein markers in diagnosis, risk stratification and prognosis.

Authors:  David Ulmert; M Frank O'Brien; Anders S Bjartell; Hans Lilja
Journal:  Nat Rev Urol       Date:  2009-07       Impact factor: 14.432

4.  The Malmö Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants.

Authors:  J Manjer; S Carlsson; S Elmståhl; B Gullberg; L Janzon; M Lindström; I Mattisson; G Berglund
Journal:  Eur J Cancer Prev       Date:  2001-12       Impact factor: 2.497

5.  Quantitative bone metastases analysis based on image segmentation.

Authors:  Y E Erdi; J L Humm; M Imbriaco; H Yeung; S M Larson
Journal:  J Nucl Med       Date:  1997-09       Impact factor: 10.057

Review 6.  Radionuclide based imaging of prostate cancer.

Authors:  Ronnie C Mease
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

Review 7.  The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma.

Authors:  B I Carlin; G L Andriole
Journal:  Cancer       Date:  2000-06-15       Impact factor: 6.860

8.  Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.

Authors:  P Sabbatini; S M Larson; A Kremer; Z F Zhang; M Sun; H Yeung; M Imbriaco; I Horak; M Conolly; C Ding; P Ouyang; W K Kelly; H I Scher
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

9.  Quality of planar whole-body bone scan interpretations--a nationwide survey.

Authors:  May Sadik; Madis Suurkula; Peter Höglund; Andreas Järund; Lars Edenbrandt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03-29       Impact factor: 9.236

10.  A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index.

Authors:  M Imbriaco; S M Larson; H W Yeung; O R Mawlawi; Y Erdi; E S Venkatraman; H I Scher
Journal:  Clin Cancer Res       Date:  1998-07       Impact factor: 12.531

View more
  60 in total

1.  Prostate cancer: Bone Scan Index made easy, at last.

Authors:  Bertrand Tombal
Journal:  Nat Rev Urol       Date:  2012-04-24       Impact factor: 14.432

2.  Analytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer.

Authors:  Aseem Anand; Michael J Morris; Reza Kaboteh; Lena Båth; May Sadik; Peter Gjertsson; Milan Lomsky; Lars Edenbrandt; David Minarik; Anders Bjartell
Journal:  J Nucl Med       Date:  2015-08-27       Impact factor: 10.057

3.  Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Authors:  Andrew J Armstrong; Aseem Anand; Lars Edenbrandt; Eva Bondesson; Anders Bjartell; Anders Widmark; Cora N Sternberg; Roberto Pili; Helen Tuvesson; Örjan Nordle; Michael A Carducci; Michael J Morris
Journal:  JAMA Oncol       Date:  2018-07-01       Impact factor: 31.777

4.  Lymphocyte function following radium-223 therapy in patients with metastasized, castration-resistant prostate cancer.

Authors:  Vahé Barsegian; Stefan P Müller; Daniel Möckel; Peter A Horn; Andreas Bockisch; Monika Lindemann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-10-08       Impact factor: 9.236

Review 5.  Imaging and evaluation of patients with high-risk prostate cancer.

Authors:  Marc A Bjurlin; Andrew B Rosenkrantz; Luis S Beltran; Roy A Raad; Samir S Taneja
Journal:  Nat Rev Urol       Date:  2015-10-20       Impact factor: 14.432

Review 6.  Prognostic Utility of PET in Prostate Cancer.

Authors:  Hossein Jadvar
Journal:  PET Clin       Date:  2015-01-22

Review 7.  Validation and clinical utility of prostate cancer biomarkers.

Authors:  Howard I Scher; Michael J Morris; Steven Larson; Glenn Heller
Journal:  Nat Rev Clin Oncol       Date:  2013-03-05       Impact factor: 66.675

Review 8.  Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons.

Authors:  Laura Evangelista; Francesco Bertoldo; Francesco Boccardo; Giario Conti; Ilario Menchi; Francesco Mungai; Umberto Ricardi; Emilio Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-09       Impact factor: 9.236

9.  A Preanalytic Validation Study of Automated Bone Scan Index: Effect on Accuracy and Reproducibility Due to the Procedural Variabilities in Bone Scan Image Acquisition.

Authors:  Aseem Anand; Michael J Morris; Reza Kaboteh; Mariana Reza; Elin Trägårdh; Naofumi Matsunaga; Lars Edenbrandt; Anders Bjartell; Steven M Larson; David Minarik
Journal:  J Nucl Med       Date:  2016-07-21       Impact factor: 10.057

10.  Prevalence of prostate cancer metastases after intravenous inoculation provides clues into the molecular basis of dormancy in the bone marrow microenvironment.

Authors:  Younghun Jung; Yusuke Shiozawa; Jingcheng Wang; Natalie McGregor; Jinlu Dai; Serk In Park; Janice E Berry; Aaron M Havens; Jeena Joseph; Jin Koo Kim; Lalit Patel; Peter Carmeliet; Stephanie Daignault; Evan T Keller; Laurie K McCauley; Kenneth J Pienta; Russell S Taichman
Journal:  Neoplasia       Date:  2012-05       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.